Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis

Journal of Cystic Fibrosis

Volumn 10, Issue 1, 2011, Pages 25-30

  Adeboyeku, D ^a   Jones, A L ^b,c   Hodson, M E ^b,c  

^a CENTRAL MIDDLESEX HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Antibiotic therapy; Cystic fibrosis; Pulmonary exacerbations

Indexed keywords

CEFTAZIDIME; TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; PREDICTION; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; CEFTAZIDIME; CYSTIC FIBROSIS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; EAR DISEASES; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; LUNG; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 78651446197     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.09.003     Document Type: Article

References (15)

1. Stick S.M., Brennan S., Murray C., Douglas T., von Ungern-Sternberg B.S., Garratt L.W., et al. Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. J Pediatr Nov. 2009, 155(5):623-628.
2. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2007.
3. Doring G., Conway S.P., Heijerman H.G., Hodson M.E., Hoiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J Oct. 2000, 16(4):749-767.
4. Flume P.A., Mogayzel P.J., Robinson K.A., Goss C.H., Rosenblatt R.L., Kuhn R.J., et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med Nov. 1 2009, 180(9):802-808.
5. Freeman C.D., Nicolau D.P., Belliveau P.P., Nightingale C.H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother Jun. 1997, 39(6):677-686.
6. Vic P., Ategbo S., Turck D., Husson M.O., Launay V., Loeuille G.A., et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child Jun. 1998, 78(6):536-539.
7. Smyth A., Tan K.H., Hyman-Taylor P., Mulheran M., Lewis S., Stableforth D., et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis-the TOPIC study: a randomised controlled trial. Lancet Feb. 12 2005, 365(9459):573-578.
8. Riethmueller J., Ballmann M., Schroeter T.W., Franke P., von B.R., Claass A., et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection Oct. 2009, 37(5):424-431.
9. Elston C., Orchard C., Wee A., Geddes D., Hodson M. Ototoxicity following once daily aminoglycoside administration in adults with CF. J Cyst Fibros 2008, 7. Suppl:A145/S37.
10. Latzin P., Fehling M., Bauernfeind A., Reinhardt D., Kappler M., Griese M. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis. J Cyst Fibros Mar. 2008, 7(2):142-146.
11. Blumer J.L., Saiman L., Konstan M.W., Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest Oct. 2005, 128(4):2336-2346.
12. Aaron S.D., Vandemheen K.L., Ferris W., Fergusson D., Tullis E., Haase D., et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet Aug. 6 2005, 366(9484):463-471.
13. Riethmueller J., Junge S., Schroeter T.W., Kuemmerer K., Franke P., Ballmann M., et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection Oct. 2009, 37(5):418-423.
14. Vinks A.A., Brimicombe R.W., Heijerman H.G., Bakker W. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics. J Antimicrob Chemother Jul. 1997, 40(1):125-133.
15. Rappaz I., Decosterd L.A., Bille J., Pilet M., Belaz N., Roulet M. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr Dec. 2000, 159(12):919-925.